

CSD/BM/SE/2025-2026
May 13, 2025

To
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 530239

Scrip Symbol: SUVEN

Dear Sir/Madam,

Sub: Outcome of the Meeting of Board of Directors of Suven Life Sciences Limited held on Tuesday, May 13, 2025

.....

Pursuant to the provisions of Regulation 30 of the SEBI (LODR) Regulations, 2015, as amended and other applicable provisions of law, we wish to inform you that the Board of Directors of the company, at its meeting held today i.e. May 13, 2025, has *inter-alia* considered and approved the following business matters.

The issue of warrants convertible into equity shares of the Company on preferential basis to Promoter Group entity and to certain Non-Promoter Persons/ Entities

Issuance of up to **6,40,02,999** (Six Crore Forty Lakhs Two Thousand Nine Hundred Ninety-Nine) fully Convertible Equity Warrants on Preferential Basis to the Promoter group entity of the Company and to certain non-promoter persons/ entities at a price of ₹ 134/- per warrant aggregating up to ₹ **857,64,01,866/-** (Rupees Eight Hundred Fifty Seven Crores Sixty Four Lakhs One Thousand Eight Hundred Sixty Six only), as mentioned in **Annexure A** (the "Proposed Allottees") in accordance with the provisions of the Companies Act, 2013, Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and other applicable statutory provisions and subject to the approval of shareholders in the Extra-Ordinary General Meeting of the Company;

Disclosure required pursuant to Regulation 30 and Schedule III of the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is enclosed herewith as **Annexure A**.

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com

We request you to take this document on your records. The Board Meeting commenced at 11:00 A.M. and concluded at 12:15 P.M.

Thanking you,
Yours faithfully,
For **Suven Life Sciences Limited**

Shrenik Soni
Company Secretary

Encl.: as above

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com

Annexure A

Details under amended Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sl. no.	particulars	details																																																
a)	type of securities proposed to be issued (viz. equity shares, convertibles etc.);	Convertible Warrants																																																
b)	type of issuance (further public offering, rights issue, depository receipts (ADR/GDR), qualified institutions placement, preferential allotment etc.);	Preferential Issue in accordance with Chapter V of the SEBI ICDR Regulations and other applicable law.																																																
c)	total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately);	Up to 6,40,02,999 Convertible Warrants of face value of ₹ 1/- each at an issue price of ₹ 134.00 per warrant, for an aggregate consideration of up to ₹ 857,64,01,866/- to Promoter Group entity and to certain non-promoter persons/ entities.																																																
d)	in case of preferential issue, the listed entity shall disclose the following additional details to the stock exchange(s):																																																	
	i. number of investors;	23																																																
	ii. names of the investors; post allotment of securities - outcome of the subscription, issue price/ allotted price (in case of convertibles),	<table border="1"> <thead> <tr> <th></th> <th>Particulars</th> <th>No. of Convertible Warrants to be allotted</th> </tr> </thead> <tbody> <tr> <td></td> <td>Promoter Group entity</td> <td></td> </tr> <tr> <td>1.</td> <td>Jasti Property and Equity Holdings Private Limited (<i>In its capacity as sole trustee of Jasti Family Trust</i>)</td> <td>3,17,68,764</td> </tr> <tr> <td></td> <td>Non-promoter persons/entities</td> <td></td> </tr> <tr> <td>2.</td> <td>QUANT MUTUAL FUND</td> <td>47,01,490</td> </tr> <tr> <td>3.</td> <td>TEJAS TRIVEDI</td> <td>37,31,343</td> </tr> <tr> <td>4.</td> <td>ABAKKUS DIVERSIFIED ALPHA FUND</td> <td>29,85,000</td> </tr> <tr> <td>5.</td> <td>3P INDIA EQUITY FUND 1</td> <td>33,58,209</td> </tr> <tr> <td>6.</td> <td>KETAN CHHOTALAL SHETH</td> <td>20,00,000</td> </tr> <tr> <td>7.</td> <td>ITI HOLDINGS AND INVESTMENT PRIVATE LIMITED</td> <td>18,65,670</td> </tr> <tr> <td>8.</td> <td>ARUN NAHAR</td> <td>15,00,000</td> </tr> <tr> <td>9.</td> <td>JAGDISH N MASTER</td> <td>15,00,000</td> </tr> <tr> <td>10.</td> <td>COBRA INDIA (MAURITIUS) LIMITED</td> <td>15,00,000</td> </tr> <tr> <td>11.</td> <td>NILESH KISHORE SHAH</td> <td>12,00,000</td> </tr> <tr> <td>12.</td> <td>NIMESH ARVIND DOSHI</td> <td>11,94,100</td> </tr> <tr> <td>13.</td> <td>ORACULAR ADVISORY PRIVATE LIMITED</td> <td>11,25,000</td> </tr> </tbody> </table>		Particulars	No. of Convertible Warrants to be allotted		Promoter Group entity		1.	Jasti Property and Equity Holdings Private Limited (<i>In its capacity as sole trustee of Jasti Family Trust</i>)	3,17,68,764		Non-promoter persons/entities		2.	QUANT MUTUAL FUND	47,01,490	3.	TEJAS TRIVEDI	37,31,343	4.	ABAKKUS DIVERSIFIED ALPHA FUND	29,85,000	5.	3P INDIA EQUITY FUND 1	33,58,209	6.	KETAN CHHOTALAL SHETH	20,00,000	7.	ITI HOLDINGS AND INVESTMENT PRIVATE LIMITED	18,65,670	8.	ARUN NAHAR	15,00,000	9.	JAGDISH N MASTER	15,00,000	10.	COBRA INDIA (MAURITIUS) LIMITED	15,00,000	11.	NILESH KISHORE SHAH	12,00,000	12.	NIMESH ARVIND DOSHI	11,94,100	13.	ORACULAR ADVISORY PRIVATE LIMITED	11,25,000
	Particulars	No. of Convertible Warrants to be allotted																																																
	Promoter Group entity																																																	
1.	Jasti Property and Equity Holdings Private Limited (<i>In its capacity as sole trustee of Jasti Family Trust</i>)	3,17,68,764																																																
	Non-promoter persons/entities																																																	
2.	QUANT MUTUAL FUND	47,01,490																																																
3.	TEJAS TRIVEDI	37,31,343																																																
4.	ABAKKUS DIVERSIFIED ALPHA FUND	29,85,000																																																
5.	3P INDIA EQUITY FUND 1	33,58,209																																																
6.	KETAN CHHOTALAL SHETH	20,00,000																																																
7.	ITI HOLDINGS AND INVESTMENT PRIVATE LIMITED	18,65,670																																																
8.	ARUN NAHAR	15,00,000																																																
9.	JAGDISH N MASTER	15,00,000																																																
10.	COBRA INDIA (MAURITIUS) LIMITED	15,00,000																																																
11.	NILESH KISHORE SHAH	12,00,000																																																
12.	NIMESH ARVIND DOSHI	11,94,100																																																
13.	ORACULAR ADVISORY PRIVATE LIMITED	11,25,000																																																

Suven Life Sciences Limited

		14.	3P INDIA EQUITY FUND 1M	11,19,403
		15.	ATMAN INVESTMENTS PRIVATE LIMITED	10,00,000
		16.	TRISHAKTI POWER HOLDINGS PRIVATE LIMITED	10,00,000
		17.	TIKRI PARTNERS LLP	7,46,260
		18.	CAMPBELL ADVERTISING PRIVATE LIMITED	4,47,760
		19.	NIMISH CHANDULAL SHAH	3,60,000
		20.	SHARAD NANDLAL SHAH	3,00,000
		21.	NEHA IYENGAR	3,00,000
		22.	SHANTIKUMAR GIRDHARLAL SHAH	1,50,000
		23.	CHARU MAHENDRA PARIKH	1,50,000
	iii. in case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument;	Not applicable		
e)	any cancellation or termination of proposal for issuance of securities including reasons thereof.	Not applicable		

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
 Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
 Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com